Usage Patterns (millions), 2004-2018 74Figure 26:Arthritis Therapeutics Market, Global, R&D Pipeline by Indication (%), 2011 76Figure 27: Arthritis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 77Figure 28: Arthritis Therapeutics Market, Osteoarthritis Therapeutics, Global R&D Pipeline by Phase (%), 2011 78Figure 29: Arthritis Therapeutics Market-Rheumatoid Arthritis, Global R&D Pipeline by Phase (%), 2011 83Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133Figure 41: GBI Research Market Forecasting Model 139
Companies Mentioned
RocheJohnson & JohnsonPfizerAbbott LaboratoriesBristol-Myers SquibbAmgen
To order this report:Therapy Industry:
SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis2.
The Strong Womans Approach to Managing Rheumatoid Arthritis3.
Defect in A20 gene expression causes rheumatoid arthritis4.
Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care5.
CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis6.
Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis7.
TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee8.
Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia® (certolizumab pegol)9.
Arthritis drug could help beat melanoma skin cancer10.
Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology11.
Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis